PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.78%
Negative revenue growth while 3141.T stands at 6.93%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-5.59%
Negative gross profit growth while 3141.T is at 14.09%. Joel Greenblatt would examine cost competitiveness or demand decline.
-26.75%
Negative EBIT growth while 3141.T is at 115.74%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-24.32%
Negative operating income growth while 3141.T is at 143.41%. Joel Greenblatt would press for urgent turnaround measures.
-22.82%
Negative net income growth while 3141.T stands at 214.87%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-22.81%
Negative EPS growth while 3141.T is at 213.97%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.81%
Negative diluted EPS growth while 3141.T is at 214.42%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Share reduction while 3141.T is at 0.25%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3141.T is at 0.13%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
152.83%
10Y revenue/share CAGR at 75-90% of 3141.T's 177.36%. Bill Ackman would press for new markets or product lines to narrow the gap.
51.72%
5Y revenue/share CAGR similar to 3141.T's 51.19%. Walter Schloss might see both companies benefiting from the same mid-term trends.
34.22%
3Y revenue/share CAGR 1.25-1.5x 3141.T's 26.16%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
137.62%
Net income/share CAGR at 50-75% of 3141.T's 230.84%. Martin Whitman might question if the firm’s product or cost base lags behind.
68.73%
5Y net income/share CAGR above 1.5x 3141.T's 39.53%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
25.56%
Positive short-term CAGR while 3141.T is negative. John Neff would see a clear advantage in near-term profit trajectory.
310.55%
10Y equity/share CAGR above 1.5x 3141.T's 195.02%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
81.59%
5Y equity/share CAGR 1.25-1.5x 3141.T's 62.59%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
35.06%
3Y equity/share CAGR 1.25-1.5x 3141.T's 28.61%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
136.36%
Below 50% of 3141.T's 343.08%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
160.00%
5Y dividend/share CAGR above 1.5x 3141.T's 56.52%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
62.50%
3Y dividend/share CAGR above 1.5x 3141.T's 20.00%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
3.80%
AR growth is negative/stable vs. 3141.T's 22.73%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
8.07%
We show growth while 3141.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
0.32%
Asset growth well under 50% of 3141.T's 11.34%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
2.65%
50-75% of 3141.T's 3.79%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
-4.27%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
-0.81%
We cut SG&A while 3141.T invests at 5.50%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.